WATARU OMORI

Last Updated :2024/07/03

Affiliations, Positions
Hiroshima University Hospital(Medical), Assistant Professor
E-mail
watsu56hiroshima-u.ac.jp
Self-introduction
I'm working on the development of biomarkers for psychiatric disorders using samples such as human blood and cerebrospinal fluid. I'm also conducting research on prevention of recurrence after electroconvulsive therapy.

Basic Information

Major Professional Backgrounds

  • 2009/04, 2011/03, Hiroshima Nishi Medical Center , Clinical Resident
  • 2011/04/01, 2011/06/30, Hiroshima University, Hospital, Clinical Fellow
  • 2011/07, 2014/03, National Hospital Organization Kure Medical Center and Chugoku Cancer Center , Clinical Resident
  • 2014/04, 2021/03, National Hospital Organization Kure Medical Center and Chugoku Cancer Center , Doctor
  • 2021/04/01, Hiroshima University, Hospital, Assistant Professor

Educational Backgrounds

  • Hiroshima University School of Medicine, 2009/03
  • Hiroshima University, 2020/11

Academic Degrees

  • Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Psychiatric science

Research Keywords

  • depression, schizophrenia
  • Biomarker, electroconvulsive therapy

Affiliated Academic Societies

  • he Japanese Society of Psychiatry and Neurology
  • The Japanese Society of General Hospital Psychiatry

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Medical Neuroscience III
  2. 2024, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2024, Undergraduate Education, 1Term, Psychiatry
  4. 2024, Undergraduate Education, 1Term, Psychiatry

Research Activities

Academic Papers

  1. Serum levels of high mobility group box-1 protein (HMGB1) and soluble receptors of advanced glycation end-products (RAGE) in depressed patients treated with electroconvulsive therapy, Neuropsychopharmacology Reports, 43(3), 359-364, 20230619
  2. ★, Increased matrix metalloproteinases in cerebrospinal fluids of patients with major depressive disorder and schizophrenia, International Journal of Neuropsychopharmacology, 23(11), 713-720, 20200716
  3. ★, Shared preventive factors associated with relapse after a response to electroconvulsive therapy in four major psychiatric disorders, Psychiatry and Clinical Neurosciences, 73(8), 494-500, 201908

External Funds

Acceptance Results of Competitive Funds

  1. 2023/04, 2026/03